Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis

Next Previous
X
Search
Trial Profile

A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Povidone iodine/dexamethasone (Primary)
  • Indications Adenovirus infections; Infectious conjunctivitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Foresight Biotherapeutics

    • Most Recent Events

    • 24 Apr 2017 Primary endpoint (Adenoviral eradication and clinical resolution of the infection) has been met, according to a Shire media release.
    • 24 Apr 2017 Results published in a Shire media release.
    • 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrial.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top